Feasibility of investigating differential proteomic expression in depression: Implications for biomarker development in mood disorders

Translational Psychiatry

Volumn 5, Issue 12, 2015, Pages

  Frye, M A ^a   Nassan, M ^a   Jenkins, G D ^a   Kung, S ^a   Veldic, M ^a   Palmer, B A ^a   Feeder, S E ^a   Tye, S J ^a   Choi, D S ^a,b   Biernacka, J M ^a  

^a MAYO CLINIC   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; GROWTH DIFFERENTIATION FACTOR 15; HEMOPEXIN; HEPSIN; MATRILYSIN; PREALBUMIN; RETINOL BINDING PROTEIN 4;

ADULT; ARTICLE; BIPOLAR DEPRESSION; BIPOLAR I DISORDER; BIPOLAR II DISORDER; BLOOD SAMPLING; CONTROLLED STUDY; DEPRESSION; DIAGNOSTIC ACCURACY; FEASIBILITY STUDY; FEMALE; HUMAN; IMMUNOASSAY; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MOOD DISORDER; POST HOC ANALYSIS; PROTEIN EXPRESSION; PROTEOMICS;

EID: 84979099358     PISSN: None     EISSN: 21583188     Source Type: Journal    
DOI: 10.1038/tp.2015.185     Document Type: Article

References (60)

1. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001; 69: 89-95.
2. Frey BN, Andreazza AC, Houenou J, Jamain S, Goldstein BI, Frye MA et al. Bio-markers in bipolar disorder: a positional paper from the international society for bipolar disorders biomarkers task force. Aust NZ J Psychiatry 2013; 47: 321-332.
3. Domenici E, Wille DR, Tozzi F, Prokopenko I, Miller S, McKeown A et al. Plasma protein biomarkers for depression and schizophrenia by multi analyte profiling of case-control collections. PLoS One 2010; 5: e9166.
4. Schwarz E, Izmailov R, Spain M, Barnes A, Mapes JP, Guest PC et al. Validation of a blood-based laboratory test to aid in the confirmation of a diagnosis of schizophrenia. Biomark Insights 2010; 5: 39-47.
5. Vapnik VN An overview of statistical learning theory. IEEE Trans Neural Netw 1999; 10: 988-999.
6. Schwarz E, Guest PC, Rahmoune H, Harris LW, Wang L, Leweke FM et al. Identification of a biological signature for schizophrenia in serum. Mol Psychiatry 2012; 17: 494-502.
7. Khandaker GM, Pearson RM, Zammit S, Lewis G, Jones PB. Association of serum interleukin 6 and C-reactive protein in childhood with depression and psychosis in young adult life: a population-based longitudinal study. JAMA Psychiatry 2014; 71: 1121-1128.
8. Setiawan E, Wilson AA, Mizrahi R, Rusjan PM, Miler L, Rajkowska G et al. Role of translocator protein density, a marker of neuroinflammation, in the brain during major depressive episodes. JAMA Psychiatry 2015; 72: 268-275.
9. Raison CL, Miller AH. Role of inflammation in depression: implications for phenomenology, pathophysiology and treatment. Mod Trends Pharmacopsychiatri 2013; 28: 33-48.
10. Raison CL, Rutherford RE, Woolwine BJ, Shuo C, Schettler P, Drake DF et al. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiatry 2013; 70: 31-41.
11. Walker AJ, Kim Y, Price JB, Kale RP, McGillivray JA, Berk M et al. Stress, inflammation, and cellular vulnerability during early stages of affective disorders: biomarker strategies and opportunities for prevention and intervention. Front Psychiatry 2014; 5: 34.
12. Li H, Hong W, Zhang C, Wu Z, Wang Z, Yuan C et al. IL-23 and TGF-beta1 levels as potential predictive biomarkers in treatment of bipolar I disorder with acute manic episode. J Affect Disord 2015; 174: 361-366.
13. First MB, Spitzer RL, Gibbon M, Gibbon W, Janet BW. Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition (SCID-I/P). Biometrics Research, New York State Psychiatric Institute: New York, NY, USA, 2002.
14. Rush AJ, Gullion CM, Basco MR, Jarrett RB, Trivedi MH. The Inventory of Depressive Symptomatology (IDS): psychometric properties. Psychol Med 1996; 26: 477-486.
15. Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 1978; 133: 429-435.
16. Spitzer RL, Kroenke K, Williams JB. Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study. Primary care evaluation of mental disorders. patient health questionnaire. JAMA 1999; 282: 1737-1744.
17. Spitzer RL, Kroenke K, Williams JB, Lowe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med 2006; 166: 1092-1097.
18. Saunders JB, Aasland OG, Babor TF, de la Fuente JR, Grant M. Development of the alcohol use disorders identification test (AUDIT): WHO collaborative project on early detection of persons with harmful alcohol consumption-II. Addiction 1993; 88: 791-804.
19. Krishhan VV, Khan IH, Luciw PA. Multiplexed microbead immunoassays by flow cytometry for molecular profiling: Basic concepts and proteomics applications. Crit Rev Biotechnol 2009; 29: 29-43.
20. Chowdhury F, Williams A, Johnson P. Validation and comparison of two multiplex technologies, luminex and mesoscale discovery, for human cytokine profiling. J Immunol Methods 2009; 340: 55-64.
21. Statland J, Donlin-Smith CM, Tapscott SJ, van der Maarel S, Tawil R. Multiplex screen of serum biomarkers in facioscapulohumeral muscular dystrophy. J Neuromuscul Dis 2014; 1: 181-190.
22. Llano DA, Devanarayan V, Simon AJ. Evaluation of plasma proteomic data for Alzheimer disease state classification and for the prediction of progression from mild cognitive impairment to Alzheimer disease. Alzheimer Dis Assoc Disord 2013; 27: 233-243.
23. Walcott BP, Patel AP, Stapleton CJ, Trivedi RA, Young AM, Ogilvy CS. Multiplexed protein profiling after aneurysmal subarachnoid hemorrhage: characterization of differential expression patterns in cerebral vasospasm. J Clin Neurosci 2014; 21: 2135-2139.
24. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM et al. Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. Standards for reporting of diagnostic accuracy. Clin Chem 2003; 49: 1-6.
25. Karolchik D, Barber GP, Casper J, Clawson H, Cline MS, Diekhans M et al. The UCSC genome browser database: 2014 update. Nucleic Acids Res 2014; 42: D764-D770.
26. Su AI, Wiltshire T, Batalov S, Lapp H, Ching KA, Block D et al. A gene atlas of the mouse and human protein-encoding transcriptomes. Proc Natl Acad Sci USA 2004; 101: 6062-6067.
27. Liu HT, Wang HC, Tao L, Li CX, Li F, Zhang YY et al. Stress-induced growth-differentiation factor 15 plays an intriguing role in cardiovascular diseases. Chin Med J (Engl) 2013; 126: 1350-1354.
28. Fuchs T, Trollor JN, Crawford J, Brown DA, Baune BT, Samaras K et al. Macrophage inhibitory cytokine-1 is associated with cognitive impairment and predicts cognitive decline - the Sydney Memory and Aging Study. Aging Cell 2013; 12: 882-889.
29. Delanghe JR, Langlois MR. Hemopexin: a review of biological aspects and the role in laboratory medicine. Clin Chim Acta 2001; 312: 13-23.
30. Maestre JR, Mateo M, Sanchez P. [Bacteremia after periodontal procedures]. Rev Esp Quimioter 2008; 21: 153-156.
31. Maes M, Delange J, Ranjan R, Meltzer HY, Desnyder R, Cooremans W et al. Acute phase proteins in schizophrenia, mania and major depression: modulation by psychotropic drugs. Psychiatry Res 1997; 66: 1-11.
32. Wu Q, Parry G. Hepsin and prostate cancer. Front Biosci 2007; 12: 5052-5059.
33. Ii M, Yamamoto H, Adachi Y, Maruyama Y, Shinomura Y. Role of matrix metalloproteinase-7 (matrilysin) in human cancer invasion, apoptosis, growth, and angiogenesis. Exp Biol Med (Maywood) 2006; 231: 20-27.
34. Szklarczyk A, Oyler G, McKay R, Gerfen C, Conant K. Cleavage of neuronal synaptosomal-associated protein of 25 kDa by exogenous matrix metallo-proteinase-7. J Neurochem 2007; 102: 1256-1263.
35. Etain B, Dumaine A, Mathieu F, Chevalier F, Henry C, Kahn JP et al. A SNAP25 promoter variant is associated with early-onset bipolar disorder and a high expression level in brain. Mol Psychiatry 2010; 15: 748-755.
36. Kotnik P, Fischer-Posovszky P, Wabitsch M. RBP4: a controversial adipokine. Eur J Endocrinol 2011; 165: 703-711.
37. Goodman AB Retinoid receptors, transporters, and metabolizers as therapeutic targets in late onset Alzheimer disease. J Cell Physiol 2006; 209: 598-603.
38. Buxbaum JN, Roberts AJ, Adame A, Masliah E. Silencing of murine transthyretin and retinol binding protein genes has distinct and shared behavioral and neuro-pathologic effects. Neuroscience 2014; 275: 352-364.
39. Bao Y, Ibram G, Blaner WS, Quesenberry CP, Shen L, McKeague IW et al. Low maternal retinol as a risk factor for schizophrenia in adult offspring. Schizophr Res 2012; 137: 159-165.
40. Maes M, Scharpe S, Van Grootel L, Uyttenbroeck W, Cooreman W, Cosyns P et al. Higher alpha 1-antitrypsin, haptoglobin, ceruloplasmin and lower retinol binding protein plasma levels during depression: further evidence for the existence of an inflammatory response during that illness. J Affect Disord 1992; 24: 183-192.
41. Raghu P, Sivakumar B. Interactions amongst plasma retinol-binding protein, transthyretin and their ligands: implications in vitamin A homeostasis and transthyretin amyloidosis. Biochim Biophys Acta 2004; 1703: 1-9.
42. Prapunpoj P, Leelawatwattana L. Evolutionary changes to transthyretin: structure-function relationships. FEBS J 2009; 276: 5330-5341.
43. Ewald H, Mors O, Koed K, Eiberg H, Kruse TA. Susceptibility loci for bipolar affective disorder on chromosome 18? A review and a study of Danish families. Psychiatr Genet 1997; 7: 1-12.
44. Pulford DJ, Adams F, Henry B, Mallinson DJ, Reid IC, Stewart CA. Chronic lithium administration down regulates transthyretin mRNA expression in rat choroid plexus. Neuropsychiatr Dis Treat 2006; 2: 549-555.
45. Nunes AF, Saraiva MJ, Sousa MM. Transthyretin knockouts are a new mouse model for increased neuropeptide Y. FASEB J 2006; 20: 166-168.
46. Zachrisson O, Mathe AA, Stenfors C, Lindefors N. Region-specific effects of chronic lithium administration on neuropeptide Y and somatostatin mRNA expression in the rat brain. Neurosci Lett 1995; 194: 89-92.
47. Hatterer JA, Herbert J, Hidaka C, Roose SP, Gorman JM. CSF transthyretin in patients with depression. Am J Psychiatry 1993; 150: 813-815.
48. Sullivan GM, Hatterer JA, Herbert J, Chen X, Roose SP, Attia E et al. Low levels of transthyretin in the CSF of depressed patients. Am J Psychiatry 1999; 156: 710-715.
49. Sullivan GM, Mann JJ, Oquendo MA, Lo ES, Cooper TB, Gorman JM. Low cere-brospinal fluid transthyretin levels in depression: correlations with suicidal ideation and low serotonin function. Biol Psychiatry 2006; 60: 500-506.
50. Fleming CE, Nunes AF, Sousa MM. Transthyretin: more than meets the eye. Prog Neurobiol 2009; 89: 266-276.
51. Stamm TJ, Lewitzka U, Sauer C, Pilhatsch M, Smolka MN, Koeberle U et al. Supraphysiologic doses of levothyroxine as adjunctive therapy in bipolar depression: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2014; 75: 162-168.
52. Sousa JC, Grandela C, Fernandez-Ruiz J, de Miguel R, de Sousa L, Magalhaes AI et al. Transthyretin is involved in depression-like behaviour and exploratory activity. J Neurochem 2004; 88: 1052-1058.
53. Herberth M, Koethe D, Levin Y, Schwarz E, Krzyszton ND, Schoeffmann S et al. Peripheral profiling analysis for bipolar disorder reveals markers associated with reduced cell survival. Proteomics 2011; 11: 94-105.
54. Stelzhammer V, Haenisch F, Chan MK, Cooper JD, Steiner J, Steeb H et al. Proteomic changes in serum of first onset, antidepressant drug-naive major depression patients. Int J Neuropsychopharmacol 2014; 17: 1599-1608.
55. Haenisch F, Alsaif M, Guest PC, Rahmoune H, Dickerson F, Yolken R et al. Multiplex immunoassay analysis of plasma shows prominent upregulation of growth factor activity pathways linked to GSK3beta signaling in bipolar patients. J Affect Disord 2014; 156: 139-143.
56. Frye MA, Thomas MA, Yue K, Binesh N, Davanzo P, Ventura J et al. Reduced concentrations of N-acetylaspartate (NAA) and the NAA-creatine ratio in the basal ganglia in bipolar disorder: a study using 3-Tesla proton magnetic resonance spectroscopy. Psychiatry Res 2007; 154: 259-265.
57. Altshuler LL Bipolar disorder: are repeated episodes associated with neuroanatomic and cognitive changes? Biol Psychiatry 1993; 33: 563-565.
58. Franklyn JA, King S, Ahlquist JA, Sheppard MC. Effect of hypothyroidism and thyroid hormone treatment of the rat on hepatic Spot 14 and thyroxine binding prealbumin mRNAs. Acta Endocrinol (Copenh) 1989; 121: 383-388.
59. Blay P, Nilsson C, Owman C, Aldred A, Schreiber G. Transthyretin expression in the rat brain: effect of thyroid functional state and role in thyroxine transport. Brain Res 1993; 632: 114-120.
60. Frye MA Clinical practice. Bipolar disorder-a focus on depression. N Engl J Med 2011; 364: 51-59.